Portage Biotech Inc. (NASDAQ:PRTG – Get Free Report) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 17,600 shares, an increase of 87.2% from the September 15th total of 9,400 shares. Based on an average daily volume of 1,760,000 shares, the short-interest ratio is presently 0.0 days. Currently, 4.2% of the company’s stock are short sold.
Portage Biotech Trading Up 1.3 %
Shares of PRTG stock traded up $0.09 on Friday, reaching $6.88. 18,680 shares of the stock were exchanged, compared to its average volume of 594,113. The business’s 50 day moving average price is $4.74 and its 200 day moving average price is $5.37. The company has a market capitalization of $7.22 million, a price-to-earnings ratio of -0.15 and a beta of 1.57. Portage Biotech has a twelve month low of $2.10 and a twelve month high of $53.20.
Portage Biotech (NASDAQ:PRTG – Get Free Report) last issued its earnings results on Thursday, August 15th. The company reported ($24.20) EPS for the quarter. Equities research analysts forecast that Portage Biotech will post -13 earnings per share for the current year.
Institutional Investors Weigh In On Portage Biotech
Portage Biotech Company Profile
Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.
See Also
- Five stocks we like better than Portage Biotech
- Stock Sentiment Analysis: How it Works
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- How to Buy Cheap Stocks Step by Step
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.